PDCD1 and sarcoma: Finally, the results of immune checkpoints’ expression showed significant differences in CD274, HAVCR2, PDCD1, and TIGIT between the two subtypes (Figure 5C), and m7GRGs might be a predictive marker for the treatment of sarcomas by targeting immune checkpoints.